59 citations,
July 2020 in “Journal of The American Academy of Dermatology” Oral minoxidil promotes hair growth but may cause side effects; needs monitoring.
May 2024 in “Australasian journal of dermatology” Bicalutamide is more effective and safer than spironolactone for treating female hair loss.
February 2024 in “Cosmoderma” Low-dose oral minoxidil can help treat male and female pattern hair loss, especially in those who can't use topical treatments or have heart health issues.
January 2022 in “Indian Dermatology Online Journal” Oral minoxidil is a safe and effective treatment for patterned hair loss.
July 2022 in “Journal of Investigative Dermatology” The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.
December 2022 in “International Journal of Women's Dermatology” The Sinclair Shedding Scale is effective for diagnosing Alopecia Areata Incognita and monitoring treatment success.
1 citations,
February 2020 in “Drug Design Development and Therapy” Low-dose Minoxidil combined with Spironolactone helps reduce hair loss and improve hair density in women, with some mild side effects.
32 citations,
April 2015 in “British Journal of Dermatology” The hair shedding scale accurately identifies abnormal hair shedding in women with long hair, with grades 5 and 6 indicating excessive shedding.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
September 2022 in “Journal of Investigative Dermatology” Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
6 citations,
December 2018 in “Australasian Journal of Dermatology” The Trichoscopy Derived Sinclair Scale offers a more accurate and reliable way to measure hair loss severity than the traditional visual method.
June 2021 in “Journal of The American Academy of Dermatology” New scale reliably assesses male hair loss with female pattern.
42 citations,
November 2019 in “Frontiers in Endocrinology” The document suggests creating a validated score to diagnose Cushing's Syndrome and considers plasma steroid profiling as a simpler diagnostic method.
March 2021 in “Journal of The European Academy of Dermatology and Venereology” Low quality of life and high HSS-29 scores increase risk of losing patients during treatment.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
17 citations,
March 2016 in “Liver international” Men with advanced liver disease and high oestrone and low testosterone levels have worse health outcomes.
14 citations,
June 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
9 citations,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
1 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
44 citations,
April 2019 in “Journal of the American Academy of Dermatology” Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
1 citations,
January 2019 in “PubMed” Baldness score can't be used to predict prostate size.
January 2009 in “Hair transplant forum international” Dr. Rodney Sinclair uses a detailed grading system to diagnose female pattern hair loss, recommends daily spironolactone and minoxidil for treatment, and believes genetics play a role in the condition.